Document |
Document Title |
WO/2023/218484A1 |
The present invention provides novel bicyclic compounds of formula (I), Formula (I) wherein, the definition of A1, A2, A3, A4, A5, Z, D, R3, R8 and R8a is described in the detailed description. which are demonstrating high pesticidal eff...
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
WO/2023/217063A1 |
The present application provides a benzo[d]isoxazole compound and use thereof. The compound has a structure represented by the following formula I. The benzo[d]isoxazole compound of the present application can induce the degradation of B...
|
WO/2023/217233A1 |
Provided are a compound having a structure of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotope isomer, a prodrug, a hydrate or a solvate thereof. The compound is capable of modulating the KIF18A protein, ther...
|
WO/2023/220715A1 |
The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutica...
|
WO/2023/219456A1 |
The present invention relates to a quinoline derivative, a preparation method therefor, and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of cancer, autoimmune diseases, fibrosis, and...
|
WO/2023/213308A1 |
The present invention provides an amide-substituted heterocyclic compound or an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, R4, Ⓐ, L, L1, X, X1, and Y1 are defin...
|
WO/2023/215367A1 |
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
WO/2023/213211A1 |
Disclosed herein is a 2,4-disubstituted-5-fluoropyrimidine derivative having a structural general formula represented by formula I: wherein, R1 and R2 are each independently selected from: R4 is selected from: Also disclosed herein is a ...
|
WO/2023/213854A1 |
Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylat
e.
|
WO/2023/215590A2 |
The present disclosure provides compounds represented by Formula (I): or salts or solvates thereof, wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, R11, and X are as defined in the specification. The present disclosure also provides composi...
|
WO/2023/208018A1 |
The present invention provides a substituted pyrimidine hydrazide compound represented by formula (I) or an optical isomer, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the substituted ...
|
WO/2023/211853A1 |
Disclosed herein are compounds comprising a pyrazole core and pharmaceutically acceptable salts thereof, and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excita...
|
WO/2023/209088A1 |
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
|
WO/2023/207241A1 |
The present invention relates to a halogen-substituted isoindoline compound represented by formula I below and use thereof. The compound of the present invention has significantly better anti-tumor activity, and can be prepared into an o...
|
WO/2023/208172A1 |
Provided are compounds containing 7-(pyrimidin-4-yl) quinolin-4(1H)-one structure of Formula (I), the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of v...
|
WO/2023/205892A1 |
The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group (1a), 1b) and (1c), that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is...
|
WO/2023/205850A1 |
The present invention relates to methods and uses for producing an insulin-producing cell from a pancreatic exocrine cell comprising contacting the pancreatic exocrine cell with an inhibitor of EZH2. The present invention also relates to...
|
WO/2023/207283A1 |
Disclosed herein is the compounds and pharmaceutically acceptable salts thereof that inhibit the Poly (ADP-ribose) polymerase (PARP) family of enzymes. The present disclosure also relates to the use of these compounds or pharmaceutically...
|
WO/2023/208165A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated product, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, an intermediate ther...
|
WO/2023/185468A9 |
The present invention belongs to the field of synthesis of heterocyclic compound drugs with a nitrogen atom as a heterocyclic atom; particularly relates to a compound used as a kinase inhibitor and the use thereof; and also relates to th...
|
WO/2023/212240A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
|
WO/2023/211256A1 |
The present invention relates to novel PIM kinase inhibitors and uses thereof and, more specifically, to a novel compound having PIM kinase inhibitory activity and a composition for the prevention, amelioration or treatment of diseases r...
|
WO/2023/208173A1 |
This disclosure provides compounds containing 6- (pyrimidin-4-yl) quinoline structure, the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of various dise...
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
WO/2023/212147A1 |
Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease.
|
WO/2023/209086A1 |
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
|
WO/2023/210792A1 |
The present invention addresses the problem of providing a new herbicide which has both a high safety for crops and an excellent herbicidal activity on weeds. The herbicide is for overcoming a food crisis accompanying the expected increa...
|
WO/2023/208108A1 |
Disclosed herein is a compound for reducing uric acid, which is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. The present invention can significantly reduce the serum uric acid level in a ra...
|
WO/2023/209368A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein n, R1, R2, R3, R4, R5, A1, A2, A3, A4 and A5 are as defined in the specification, processes...
|
WO/2023/208143A1 |
The present application relates to a pyrazole-substituted cyclopentanol ester derivative and use thereof, and in particular to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
|
WO/2023/211213A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport and injection ability, light-emitting abilit...
|
WO/2023/207556A1 |
The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound represented by formula (A) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate ...
|
WO/2023/209028A1 |
The invention relates to sulphonyl benzene derivatives, in particular to fluorinated sulphonyl benzene derivatives. It is provided a compound of formula (I) or general formula (IA) wherein X is fluorine; A is either O or NH; B is an amin...
|
WO/2023/207284A1 |
Disclosed are piperazine derivatives and pharmaceutically acceptable salts thereof that inhibit the Poly (ADP-ribose) polymerase (PARP) family of enzymes. Also disclosed is the use of these compounds or pharmaceutically acceptable salts ...
|
WO/2023/206665A1 |
The present invention relates to a process for unprotected asymmetric preparation of nicotine. Specifically, optically pure nicotine is prepared from a nicotinate as the starting material through four reactions, wherein the preparation o...
|
WO/2023/211990A1 |
Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-ga...
|
WO/2023/207960A1 |
The present invention relates to a substituted fused pyrimidine-based derivative, a method for preparing same, and pharmaceutical use of a pharmaceutical composition comprising the derivative. Specifically, the present invention relates ...
|
WO/2023/207875A1 |
Provided herein are CDK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provide herein is a method of their use for treating, preventing, or ameliorating a chemotherapy-induced gastrointestinal ...
|
WO/2023/211238A1 |
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus is useful as a therapeutic agent for EGFR-related ...
|
WO/2023/201423A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2023/205272A1 |
The present application provides compounds and methods for treating various diseases such as malaria and cancer.
|
WO/2023/201421A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2023/202655A1 |
Provided herein are a compound of Formula (I), a pharmaceutical composition comprising said compound, and method of use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpress...
|
WO/2023/205173A1 |
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...
|
WO/2023/202582A1 |
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...
|
WO/2023/205465A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
|
WO/2023/201780A1 |
Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
|
WO/2023/205226A1 |
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting mutant KIT prote...
|
WO/2023/205219A1 |
Provided herein are E2 binding PROTACS and uses thereof.
|